EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Incidence of Factor VII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate



Incidence of Factor VII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate



Thrombosis & Haemostasis 73(2): 215-218



The incidence of factor VIII inhibitor was studied in a cohort of 56 previously untreated patients with severe hemophilia A (factor VIII below 1 U/dl). They received only one brand of highly purified factor VIII concentrate (HPSD-VIII) prepared by conventional chromatography with a solvent-detergent step for viral inactivation. Follow-up since the first infusion of HPSD-VIII was from 1 to 76 months (mean = 29) and cumulative exposure days (CED) from 1 to over 100 (median = 26). Five patients (9%) developed an inhibitor after 6 to 19 CED, only one being a high responder (2%), showing a low incidence of inhibitor compared with previous studies using high purity plasma-derived or recombinant products.

(PDF emailed within 1 workday: $29.90)

Accession: 008845170

Download citation: RISBibTeXText

PMID: 7792732



Related references

Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate. Thrombosis and Haemostasis 82(4): 1247-1249, 1999

Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thrombosis and Haemostasis 71(5): 544-547, 1994

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Critical Reviews in Oncology/Hematology 81(1): 82-93, 2012

Zero incidence of inhibitor development in previously treated haemophilia A, HIV-negative patients upon exposure to a plasma-derived high-purity and double viral inactivated factor VIII concentrate. Haemophilia 4(1): 21-24, 1999

Multicenter comparison of inhibitor development on plasma-derived vs recombinant factor VIII in severe hemophilia A patients. Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15, 1999

Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?. Seminars in Thrombosis and Hemostasis 40(2): 269-270, 2014

Clinical study comparing the factor IX recovery of a plasma derived and a recombinant factor IX concentrate vs BeneFixTM in previously treated subjects with moderate or severe hemophilia B. Blood 94(10 SUPPL 1 PART 1): 238a, Nov 15, 1999

Comparison of the detectability of UBOs in Neurofibromatosis Type I patients with proton density-weighted and FLAIR sequences in 3T MRI. European Journal of Paediatric Neurology, 2018

Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 90(9): 1288-1290, 2005

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 8(6): 1256-1265, 2010

Incidence of factor VIII inhibitor development in previously untreated hemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Annals of Hematology 78(SUPPL 1): A10, 1999

Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies. Journal of Thrombosis and Haemostasis 6(2): 390-392, 2007

Successful treatment of an acute subdural hematoma with recombinant factor VII concentrate in a 3-year-old boy with severe hemophilia A and a highly titered inhibitor. Annals of Hematology 76(SUPPL 1): A80, 1998

Pharmacokinetic analysis of plasma-derived and recombinant factor IX concentrates in previously treated patients with moderate or severe hemophilia B. Annals of Hematology 80(Supplement 1): A16, 2001